Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

A huge leap in fines for misusing mobility parks, help with childcare and access to new drugs are just some of the measures ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

In a triple whammy of good news, 1 October heralds the beginning of the funding of two major health products and a welcome contribution to early childhood fees, Prime Minister Christopher Luxon says.

Merck (MRK) is one of the worst-performing stocks in the Dow Jones Industrial Average (DJIA) on Thursday. The US government ...

A total of 27 women received the breast cancer vaccine and the clinical trial is preparing its second phase. Results are ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

“Keytruda is the first drug to be funded and made available from the $604 million boost we made to Pharmac in June. It will be life-changing for people with advanced triple-negative breast ...